Company Filing History:
1 out of 1,778 
1 out of 1,976 
Years Active: 2018
Title: Jeff Dantzler: Innovator in Human CD30 Ligand Antigen Binding Proteins
Introduction
Jeff Dantzler is a notable inventor based in Seattle, WA. He has made significant contributions to the field of biotechnology, particularly in the development of human CD30 ligand antigen binding proteins. His work has implications for therapeutic applications and advancements in medical science.
Latest Patents
Dantzler holds a patent for "Human CD30 ligand antigen binding proteins." This patent encompasses compositions and methods related to human CD30L antigen binding proteins. The compositions include human CD30L antigen binding proteins, polynucleotides encoding these proteins, vectors comprising the polynucleotides, host cells, and pharmaceutical compositions. Additionally, the patent outlines methods for making and utilizing these compositions.
Career Highlights
Throughout his career, Jeff Dantzler has worked with prominent companies in the biotechnology sector. He has been associated with Novo Nordisk A/S and Amgen Inc., where he has contributed to various innovative projects and research initiatives.
Collaborations
Dantzler has collaborated with esteemed colleagues, including Mette Dahl Andersen and Richard Jeffrey Armitage. These collaborations have furthered his research and development efforts in the field of antigen binding proteins.
Conclusion
Jeff Dantzler's work in the development of human CD30 ligand antigen binding proteins showcases his innovative spirit and dedication to advancing biotechnology. His contributions are valuable to the scientific community and have the potential to impact therapeutic strategies in the future.